Results 161 to 170 of about 82,732 (241)

Minimally Invasive Nephrectomy for the Management of Polycystic Kidney Disease: The Hilum-First Technique. [PDF]

J Clin Med
Shweiki A, Khalayleh H, Rivin M, Shabaneh S, Khalaileh A, Imam A.   +5 more
europepmc   +1 more source

Unraveling the Genetic Links Between Polycystic Kidney Disease and Hypertension Through ARL13B. [PDF]

Int J Nephrol Renovasc Dis
Chen J, Song L, Mei S, Huang J, Fu L, Zhou C, Hu X, Zhang L, Xue C, Mao Z.   +9 more
europepmc   +1 more source

Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025. [PDF]

Clin Kidney J
Cornec-Le Gall E, Ong ACM.
europepmc   +1 more source

Clinical Factors Associated With Intracranial Aneurysms in Patients With Autosomal Dominant Polycystic Kidney Disease. [PDF]

Cureus
Fuchinoue Y, Sakaeyama Y, Matsuzaki R, Kubota S, Abe M, Terazono S, Nemoto M, Sugo N.   +7 more
europepmc   +1 more source

Functional Analysis of a De Novo Monoallelic NEK8 Variant Supports Pathogenicity for a Polycystic Kidney Disease Phenotype

Kidney International Reports
Whitney S. Thompson, Chuan Chen, Hana Yang, Theodora A. Potretzke, Tracy A. Baker, Sara Hassan, Carl H. Cramer, Peter C. Harris, Kun Ling, Christian Hanna   +9 more
doaj   +1 more source

Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease. [PDF]

Nucleic Acids Res
Lakhia R, Song C, Biggers L, Zumwalt M, Alvarez J, Somasundaram A, Ramalingam H, Cobo-Stark P, Patel V.   +8 more
europepmc   +1 more source

Impact of polycystic kidney disease on outcomes after renal transplantation: systematic review and meta-analysis. [PDF]

Ren Fail
Liu C, Yan F, Zhong M, Niu Y.
europepmc   +1 more source

Genome editing strategies to generate working models of polycystic kidney disease. [PDF]

Sci Rep
Migliorero M, Marsalla D, Vallone FE, Ragone A, Saglia C, Scolari C, Bracciamà V, Arruga F, Sorbini M, Faini AC, Peruzzi L, Vaisitti T, Deaglio S.   +12 more
europepmc   +1 more source

Reduction of polycystic kidney and liver volumes in a patient with tolvaptan-resistant autosomal dominant polycystic kidney disease and acromegaly during lanreotide therapy. [PDF]

CEN Case Rep
Takenaka S, Hattanda F, Kawamura T, Watanabe-Kusunoki K, Nakazawa D, Kameda H, Amengual O, Atsumi T, Nishio S.   +8 more
europepmc   +1 more source

Kcnn4/KCa3.1 inhibition blunts polycystic kidney disease progression in mouse models. [PDF]

JCI Insight
Yao G, Kurbegovic A, Parrot C, Foley W, Roman W, Alper SL, Trudel M.   +6 more
europepmc   +1 more source